Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

JSPR - Jasper Therapeutics Inc


IEX Last Trade
21.75
1.660   7.632%

Share volume: 165,776
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$20.09
1.66
8.26%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
13.01%
1 Month
18.09%
3 Months
-9.54%
6 Months
9.00%
1 Year
75.81%
2 Year
9.00%
Key data
Stock price
$21.75
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$4.00 - $31.01
52 WEEK CHANGE
$0.90
MARKET CAP 
329.296 M
YIELD 
N/A
SHARES OUTSTANDING 
15.105 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.85
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$166,984
AVERAGE 30 VOLUME 
$163,248
Company detail
CEO:
Region: US
Website: jaspertherapeutics.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

jasper therapeutics is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. jasper’s lead compound, jsp191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.

Recent news